This Article Full Text Full Text (PDF) All Versions of this Article: 113/22/2572    most recent CIRCULATIONAHA.105.602136v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McAlister, F. A. Articles by Tu, J. V. Search for Related Content PubMed PubMed Citation Articles by McAlister, F. A. Articles by Tu, J. V. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID Medline Plus Health Information Heart Failure Related Collections Health policy and outcome research Congestive Cardiovascular Pharmacology

(Circulation. 2006;113:2572-2578.)
© 2006 American Heart Association, Inc.

Heart Failure

Aspirin Use and Outcomes in a Community-Based Cohort of 7352 Patients Discharged After First Hospitalization for Heart Failure

Finlay A. McAlister, MD, MSc; William A. Ghali, MD, MPH; Yanyan Gong, MSc; Jiming Fang, PhD; Paul W. Armstrong, MD; Jack V. Tu, MD, PhD

From the Division of General Internal Medicine (F.A.M.) and the Division of Cardiology (P.W.A.), University of Alberta, Edmonton, Canada; the Division of General Internal Medicine, University of Calgary, Calgary, Canada (W.A.G.); the Institute for Clinical Evaluative Sciences, University of Toronto, Toronto, Canada (Y.G., J.F.); and the Division of General Internal Medicine, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Canada (J.V.T.).

Correspondence to Dr F. McAlister, 2E3.24 WMC, University of Alberta Hospital, 8440 112 Street, Edmonton, Alberta, Canada T6G 2R7. E-mail- Finlay.McAlister{at}ualberta.ca

Received November 16, 2005; revision received March 23, 2006; accepted March 24, 2006.

Background— The safety of aspirin in heart failure (HF) has been called into question, particularly in those patients (1) without coronary disease, (2) with renal dysfunction, or (3) treated with low-dose angiotensin-converting enzyme (ACE) inhibitors and high-dose aspirin.

Methods and Results— We examined prescription patterns and outcomes (all-cause mortality and/or HF readmission) in patients discharged from 103 Canadian hospitals between April 1999 and March 2001 after a first hospitalization for HF. Of 7352 patients with HF (mean age, 75 years; 44% without coronary disease and 29% with renal dysfunction), 2785 (38%) died or required HF readmission within the first year. Compared with nonusers, aspirin users were no more likely to die or require HF readmission (hazard ratio [HR], 1.02 [0.91 to 1.16]), even in patients without coronary disease (HR, 0.98 [0.78 to 1.22]) or patients with renal dysfunction (HR, 1.13 [0.94 to 1.36]). On the other hand, users of ACE inhibitors were less likely to die or require HF readmission (HR, 0.87 [0.79 to 0.96]), even if they were using aspirin (HR, 0.86 [0.77 to 0.95]). There were no dose-dependent interactions between aspirin and ACE inhibitors.

Conclusions— In this observational study, aspirin use was not associated with an increase in mortality rates or HF readmission rates, and aspirin did not attenuate the benefits of ACE inhibitors, even in patients without coronary disease, patients with renal dysfunction, or patients treated with high-dose aspirin and low-dose ACE inhibitors.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				H.-C. Diener, H. Mattle, M. Böhm, and F. Ruschitzka CHAPTER 15a The Heart and the Brain ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text]

				F. A. McAlister, D. T. Eurich, S. R. Majumdar, and J. A. Johnson The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy Eur J Heart Fail, July 1, 2008; 10(7): 703 - 708. [Abstract] [Full Text] [PDF]

				R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 776S - 814S. [Abstract] [Full Text] [PDF]

				A. Y. Gasparyan, T. Watson, and G. Y.H. Lip The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1829 - 1843. [Abstract] [Full Text] [PDF]

				N U Weir An update on cardioembolic stroke Postgrad. Med. J., March 1, 2008; 84(989): 133 - 142. [Abstract] [Full Text] [PDF]

				M. Guazzi and G. Reina Letter by Guazzi and Reina Regarding Article, "Aspirin Use and Outcomes in a Community-Based Cohort of 7352 Patients Discharged After First Hospitalization for Heart Failure" Circulation, January 30, 2007; 115(4): e54 - e54. [Full Text] [PDF]

				F. A. McAlister, W. A. Ghali, Y. Gong, J. Fang, J. V. Tu, and P. W. Armstrong Response to Letter Regarding Article, "Aspirin Use and Outcomes in a Community-Based Cohort of 7352 Patients Discharged After First Hospitalization for Heart Failure" Circulation, January 30, 2007; 115(4): e55 - e55. [Full Text] [PDF]

				Should Heart Failure Patients Receive Aspirin? Journal Watch Cardiology, July 12, 2006; 2006(712): 2 - 2. [Full Text]

				P. Jhund and J. J.V. McMurray Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?: Choosing Between the Scylla of Observational Studies and the Charybdis of Subgroup Analysis Circulation, June 6, 2006; 113(22): 2566 - 2568. [Full Text] [PDF]